Trial Profile

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GEN 3014 (Primary) ; Daratumumab/hyaluronidase
Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Multiple myeloma
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Genmab A/S

08 May 2025 Planned End Date changed from 31 Dec 2026 to 31 Jul 2025.
08 May 2025 Planned primary completion date changed from 1 Mar 2025 to 30 Jun 2025.
10 Mar 2025 According to a Genmab media release, as stipulated by the development and option agreement between Genmab and J&J for HexaBody-CD38, company provided J&J with data from clinical proof-of-concept study in multiple myeloma, including a head-to-head comparison with DARZALEX FASPRO (daratumumab and hyaluronidase fihj).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com